Improving Routes in API Manufacturing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Improving Routes in API Manufacturing
Catalytic routes to producing atorvastatin and sitagliptin are recent advancements.


Pharmaceutical Technology


"Macugen" (pegaptanib sodium), which was approved by FDA in 2004, is an example of a commercial aptamer. The drug was developed by Eyetech Pharmaceuticals, which was acquired by OSI Pharmaceuticals (Melville, NY) in 2005. Pegaptanib is a covalent conjugate of a 28-mer oligonucleotide that terminates in a pentylamino linker, to which two 20-kilodalton monomethoxy polyethylene glycol units are covalently attached via the two amino groups on a lysine residue (5).

References

1. K. Holt-Tiffin et al., "Nitrilase-Catalyzed Desymmetrization of 3-Hydroxyglutaronitrile: Preparation of a Statin Side-Chain Intermediate," Org. Process Res. Dev. 10 (3), 661–665 (2006).

2. P. Van Arnum, "Achieving Enantioselectivity in Synthesizing APIs and Intermediates," Pharm. Technol. 30 Technology Outlook: APIs, Intermediates, and Formulation suppl. s20–s25 (2006).

3. P. Van Arnum, "Optimizing Strategies for API Synthesis and Formulation Development," Pharm. Technol. 30 (11), 44–48 (2006).

4. M. Stanek et al., "Preparation of Alkylated N- or Amino, Ammonium or Spirobicyclic Ammonium Group-containing, Cross-linked Polymers," US Patent 7105631, Sept. 12, 2006.

5. Drugs@FDA, http://www.fda.gov/cder/foi/label/2006/021756s006,s007lbl.pdf (accessed June 4, 2007).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here